Nuvalent Inc - ESG Rating & Company Profile powered by AI
This webpage includes a questions and answers table for Nuvalent Inc. The ESG assessment for Nuvalent Inc represents the company's reporting of the United Nations SDGs. Jump to the end of this webpage for potential risks for Nuvalent Inc based on industry, location and size.
Nuvalent Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 4.8, social score of 6.4 and governance score of 8.0.
6.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 511 | Wakamoto Pharmaceutical Co Ltd | 6.5 | High |
| 511 | X4 Pharmaceuticals Inc | 6.5 | High |
| 535 | Nuvalent Inc | 6.4 | High |
| 535 | Al Mansour Pharmaceuticals Industries Co | 6.4 | High |
| 535 | Alpine Immune Sciences Inc | 6.4 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Nuvalent Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Nuvalent Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Nuvalent Inc report the average age of the workforce?
Sign up for free to unlockDoes Nuvalent Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Nuvalent Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Nuvalent Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Nuvalent Inc offer flexible work?
Sign up for free to unlockDoes Nuvalent Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Nuvalent Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Nuvalent Inc conduct supply chain audits?
Sign up for free to unlockDoes Nuvalent Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Nuvalent Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Nuvalent Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Nuvalent Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Nuvalent Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Nuvalent Inc disclose water use targets?
Sign up for free to unlockDoes Nuvalent Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Nuvalent Inc have a product recall in the last two years?
Sign up for free to unlockDoes Nuvalent Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Nuvalent Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Nuvalent Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Nuvalent Inc disclose parental leave metrics?
Sign up for free to unlockDoes Nuvalent Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Nuvalent Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Nuvalent Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Nuvalent Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Nuvalent Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Nuvalent Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Nuvalent Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Nuvalent Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Nuvalent Inc disclose its waste policy?
Sign up for free to unlockDoes Nuvalent Inc report according to TCFD requirements?
Sign up for free to unlockDoes Nuvalent Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Nuvalent Inc disclose energy use targets?
Sign up for free to unlockDoes Nuvalent Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Nuvalent Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Nuvalent Inc
These potential risks are based on the size, segment and geographies of the company.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.